Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.270
+0.100 (8.55%)
Mar 24, 2026, 11:54 AM EDT - Market open
Immunic Employees
Immunic had 92 employees as of December 31, 2025. The number of employees increased by 1 or 1.10% compared to the previous year.
Employees
92
Change
1
Growth
1.10%
Revenue / Employee
n/a
Profits / Employee
-$1,079,689
Market Cap
165.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Sep 30, 2025 | 90 | 5 | 5.88% |
| Jun 30, 2025 | 90 | 5 | 5.88% |
| Mar 31, 2025 | 90 | 10 | 12.50% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Sep 30, 2024 | 85 | 5 | 6.25% |
| Jun 30, 2024 | 85 | 10 | 13.33% |
| Mar 31, 2024 | 80 | 7 | 9.59% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Sep 30, 2023 | 80 | 15 | 23.08% |
| Jun 30, 2023 | 75 | 15 | 25.00% |
| Mar 31, 2023 | 73 | 18 | 32.73% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Sep 30, 2022 | 65 | 13 | 25.00% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 55 | 15 | 37.50% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Sep 30, 2021 | 52 | 24 | 85.71% |
| Jun 30, 2021 | 45 | - | - |
| Mar 31, 2021 | 40 | 14 | 53.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 220 |
| Codexis | 146 |
| Heron Therapeutics | 128 |
| Nkarta | 105 |
| Corbus Pharmaceuticals Holdings | 36 |
| vTv Therapeutics | 26 |
| Unicycive Therapeutics | 23 |
| Sagimet Biosciences | 14 |
IMUX News
- 14 days ago - Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PRNewsWire
- 21 days ago - Immunic to Participate in Investor Conferences in March - PRNewsWire
- 26 days ago - Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Immunic Announces Closing of Oversubscribed Private Placement Financing - PRNewsWire
- 5 weeks ago - Immunic Stock Jumps After Pricing $400 Million Private Placement - Benzinga
- 5 weeks ago - Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - PRNewsWire
- 6 weeks ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PRNewsWire